Market Overview

ICON Wins Multiple Categories in 2019 CRO Leadership Awards

Share:

ICON recognised for specialised services offering across product
development lifecycle

ICON plc, (NASDAQ:ICLR) a global provider of drug development
and commercialisation services to the pharmaceutical, biotechnology and
medical device industries, has won awards across several categories in
the annual CRO Leadership Awards.

ICON received 2019 CRO Leadership Awards in five categories, each
further divided into three groups – Big Pharma, Small Pharma, and
Overall. In three categories, ICON took awards in all three groups.

Winning categories:

  • Compatibility (Overall, Big Pharma, Small Pharma)
  • Expertise (Small Pharma)
  • Phase IV (Overall, Big Pharma, Small Pharma)
  • Quality (Overall, Big Pharma, Small Pharma)
  • Reliability (Overall, Big Pharma)

This builds on ICON's success in 2018 when the company won a CRO Phase
IV Leadership Award (Overall, Big Pharma).

For the 2019 CRO Leadership Awards, Life Science Leader magazine
again teamed up with Industry Standard Research (ISR) to determine the
award recipients. Sixty contract research organisations were assessed on
more than 20 performance metrics in ISR's annual CRO Quality
Benchmarking survey
.

Survey participants were recruited from pharma and biopharma companies
of all sizes and were screened for decision-making influence related to
working with contract research organisations.

"These awards are a testament to the expertise of ICON's operational and
scientific professionals, and demonstrate the ownership and outcomes
focus we bring to all phases of the drug development process. It is
especially pleasing to see us recognised both by big and small biopharma
companies alike, commented Dr Steve Cutler, Chief Executive Officer,
ICON plc.

"These awards recognise ICON's comprehensive services, spanning the
entire product development lifecycle and providing seamless solutions
that ultimately lead to better outcomes for our customers".

"Life Science Leader is proud to once again be working with ISR
Reports to honor those CROs that have proven themselves to be the top
performers in Compatibility, Capabilities, Expertise, Quality,
Reliability, and Phase IV," commented Ed Miseta, Executive Editor, Life
Science Leader
.

"The winners are selected by their pharma clients, who rate their CROs
on 20+ different performance metrics. We believe the CROs receiving an
award this year are truly at the top of their class and are deserving of
this recognition. Being a top performer in any of these categories shows
a level of expertise and commitment to clinical trials and serving the
needs of biopharmaceutical companies and their patients."

"Industry Standard Research continues to consider it an honor to provide
the primary market research data for Life Science Leader's CRO
Leadership Awards. ISR's stringent screening processes ensures that only
highly qualified industry decision makers participate in our CRO
benchmarking market research," commented Andrew Schafer, President of
Industry Standard Research.

"This is paramount as we ask the research participants to provide
experiential, not perceptual, feedback on their involvement with
contract suppliers over the past 18 months. The data enables users of
ISR's market research to make confident business decisions based on the
experiences of their industry peers."

ICON previously received CRO Leadership Awards in 2018 and 2015.

A full list of ICON's industry awards can be viewed at www.iconplc.com/awards.

About ICON plc

ICON plc is a global provider of outsourced drug development and
commercialisation solutions and services to the pharmaceutical,
biotechnology, medical device and government and public health
organisations. The company specialises in the strategic development,
management and analysis of programs that support clinical development -
from compound selection to Phase I-IV clinical studies. With
headquarters in Dublin, Ireland, ICON currently, operates from 90
locations in 37 countries and has approximately 13,680 employees.

Further information is available at www.iconplc.com

ICON/ICLR-G

This press release contains forward-looking statements. These
statements are based on management's current expectations and
information currently available, including current economic and industry
conditions. These statements are not guarantees of future performance or
actual results, and actual results, developments and business decisions
may differ from those stated in this press release. The forward-looking
statements are subject to future events, risks, uncertainties and other
factors that could cause actual results to differ materially from those
projected in the statements, including, but not limited to, the ability
to enter into new contracts, maintain client relationships, manage the
opening of new offices and offering of new services, the integration of
new business mergers and acquisitions, as well as economic and global
market conditions and other risks and uncertainties detailed from time
to time in SEC reports filed by ICON, all of which are difficult to
predict and some of which are beyond our control. For these reasons, you
should not place undue reliance on these forward-looking statements when
making investment decisions. The word "expected" and variations of such
words and similar expressions are intended to identify forward-looking
statements. Forward-looking statements are only as of the date they are
made and we do not undertake any obligation to update publicly any
forward-looking statement, either as a result of new information, future
events or otherwise. More information about the risks and uncertainties
relating to these forward-looking statements may be found in SEC reports
filed by ICON, including its Form 20-F, F-1, S-8 and F-3, which are
available on the SEC's website at 
http://www.sec.gov.

View Comments and Join the Discussion!